EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Effect Of Long-Term Use Of Antithrombotics And Statins On COVID-19 Mortality And Clinical Severity

Emrah Aksakal, Selim Aydemir, Faruk Aydınyılmaz, Murat Özmen

Recent Trends in Pharmacology · 2024

DOI: 10.62425/rtpharma.1534162 ↗
AbstractBibliografische Angaben

Abstract

Objective: Coronavirus Disease-2019 (COVID-19), has affected the whole world and is still an important disease with its mutations. In our study, we aimed to evaluate the effects of antithrombotic agents [acetylsalicylic acid (ASA), P2Y12 inhibitors, oral anticoagulants (OACs)] and statin treatments used before hospitalization on COVID-19 mortality and clinical severity. Methods: A retrospective study was conducted on 5577 patients hospitalized with positive swab tests or findings consistent with COVID-19 on computed tomography. The 6-month mortality, in-hospital mortality, need for intensive care and intubation, and recurrent hospitalization outcomes of patients receiving chronic ASA (n=1210), P2Y12 inhibitors (n=357), OACs (n=1192), and statin (n=607) treatment were evaluated. Results: The 6-month mortality rate was 13.5% (n=754), in-hospital mortality rate was 11.2% (n=627), the rate of admission to the intensive care unit was 16.1% (n=897), the need for intubation was 8.8% (n=493), and the rate of recurrent hospitalization was 10.4% (n=579). ASA and OACs reduced all outcomes. P2Y12 inhibitors provided benefit in other endpoints except intubation. Statins used before hospitalization did not provide a statistically significant decrease in 6-month mortality (p: 0.06), but were associated with a decrease in the rates of in-hospital mortality, need for intensive care, recurrent hospitalization, and intubation. Conclusion: We found that long-term ASA, P2Y12 inhibitors, OACs and statin treatments used before hospitalization in patients hospitalized with COVID-19, reduced COVID-19 mortality and clinical severity. We think that these treatments may be beneficial in selected patient groups where post-COVID effects are observed.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →